Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $25.57

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $25.5714.

Several equities analysts have recently commented on the company. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the company a "buy" rating in a research report on Monday, August 18th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price on the stock. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Wedbush upped their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th.

Stoke Therapeutics Price Performance

NASDAQ STOK traded down $0.12 during trading on Tuesday, reaching $19.56. 1,149,629 shares of the company's stock were exchanged, compared to its average volume of 867,662. The business has a 50 day moving average price of $13.31 and a 200-day moving average price of $10.41. The stock has a market capitalization of $1.07 billion, a P/E ratio of 23.01 and a beta of 1.15. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $19.91.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 13,712 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $15.00, for a total value of $205,680.00. Following the transaction, the general counsel owned 19,631 shares of the company's stock, valued at approximately $294,465. This represents a 41.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Barry Ticho sold 6,471 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider directly owned 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,432 shares of company stock worth $345,775 in the last ninety days. 9.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of large investors have recently added to or reduced their stakes in STOK. GAMMA Investing LLC grew its position in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares in the last quarter. BNP Paribas Financial Markets grew its position in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after buying an additional 3,591 shares in the last quarter. AlphaQuest LLC acquired a new stake in Stoke Therapeutics during the first quarter worth approximately $72,000. Finally, US Bancorp DE grew its position in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after buying an additional 11,108 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.